Latest News

Focusing on cutting-edge technologies and research advancements,
sharing Aniphe BioLab’s achievements in scientific innovation, Professional insights
and practical experience in the fields of laboratory animals and preclinical research.

Publish an article

2026-10-29

Naming Genetically Engineered Mice (Part II): From Being Understandable to Being Written Correctly

2026-10-29

How should a multi-disease composite mouse model be constructed? Let’s take a look at the CKM approach.

2026-08-12

2026 CKM Guidelines Released: Chronic Diseases Enter the Era of Integrated Cardiorenal-Metabolic Management—It’s Time to Rethink Animal Models

2026-08-12

A Guide to Safe Mouse Handling | Manual on Mouse Transport Protocols and Troubleshooting

Jointly Building Standards, Advancing with Precision | Aniphe BioLab, in collaboration with multiple institutions, has released a group standard for human prostate organoids.

Recently, the “General Requirements for the Construction, Culture, and Identification of Human Prostate Cancer Organoids” (T/CRHA 215—2025), jointly drafted by Jiangsu Aniphe BioLab Co., Ltd. in collaboration with The First Affiliated Hospital of Southeast University, the Jiangsu Provincial Center for Disease Control and Prevention, China Pharmaceutical University, and several other institutions, has been officially released and put into effect by the Chinese Research Hospital Association.

Organoids are three-dimensional microorganoid models generated in vitro from stem cells or tissue cells. 。 It can closely mimic real organs in both structure and function, earning it the nickname “mini‑organs in a dish.” The core value of this technology lies in providing an experimental platform that more accurately reflects human physiology, thereby advancing disease research, drug screening, and personalized medicine. In particular, it holds tremendous potential to replace conventional cell‑based and animal models, especially in areas such as cancer and genetic disorders, making it one of the most promising frontiers in contemporary biomedicine.

This standard focuses on the end-to-end technical framework for human-derived prostate cancer organoids, spanning their construction, culture, and characterization. It aims to address longstanding issues—such as poor comparability of research findings and insufficient data reliability—stemming from the lack of standardized operational procedures.

As one of the drafting participants of this standard , Jiangsu Aniphe BioLab Co., Ltd. has, in the field of organoid technology, Especially in the areas of tumor organoid model construction and drug screening applications. Its profound expertise is devoted to the development of standards.

The release of this group standard not only sets a technological benchmark for the industry, but also It has provided clear guidelines for the service upgrade of Aniphe BioLab Co., Ltd. The company has optimized and systematically upgraded its end-to-end service platform for the construction, culture, and pharmacological evaluation of human‑derived prostate cancer organoids, ensuring that every model delivered to clients exhibits high reliability, robust stability, and strong clinical relevance.

Looking ahead, we will continue to build on this group standard as a cornerstone, working hand in hand with partners from industry, academia, research institutions, and the medical community to jointly advance the standardization and industrialization of organoid technology. Our goal is to translate this innovative technology into a powerful driver for accelerating new‑drug development and precision medicine—more efficiently and with greater reliability.

[Good News] Aniphe BioLab has won the provincial first prize in the “Right Here in Jiangsu” Youth Entrepreneurship Competition!

Big news! The LABUS 7T small-animal high-frequency color ultrasound imaging service is now available!